Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy

Autor: Mehmet Orhan Ayyildiz, Merih Kızıl Çakar, Serdal Korkmaz, Mehmet Sinan Dal, Alparslan Merdin, Fevzi Altuntaş, Filiz Bekdemir, Kadir Ilkkilic, Ali Kaya, Sibel Hacioglu, Mehmet Hilmi Dogu, Abdullah Karakuş, Emre Tekgündüz

Publikováno v: Journal of Chemotherapy. 30:44-48

We hereby report our multicentre, retrospective experience with CLARA in patients with fludarabine/cytarabine/G-CSF (FLAG) refractory AML. The study included all consecutive R/R AML patients, who received CLARA salvage during October 2010–October 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3488241b25411d455177d8be340a4453
https://doi.org/10.1080/1120009x.2017.1396017

Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations

Autor: Ferrari A., Bussaglia E., Úbeda J., Facchini L., Aventin A., Sierra J., Nomdedéu J.F.

Publikováno v: HEMATOLOGICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Acute promyelocytic leukaemia (APL) is a unique clinicobiologic entity that can be successfully treated with All-trans Retinoic Acid ATRA-based regimens. Some cases of acute myeloid leukaemia (AML) with nucleophosmin (NPM) mutations have an immunophe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::24ba9cd1a1c8bd362200fae0765c1ae2
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=10700